Dr. Masood Khan

Biography

Masood Khan, PhD, Vice President of Biopharmaceutical Services, is an internationally renowned thought leader in the field of regulatory compliant ligand-binding assays (LBAs).  Dr. Khan brings over 25 years of unparalleled knowledge of immunoanalytical sciences and technologies to head scientific operations and compliance of large molecule bioanalyses at Alliance Pharma.  To his credit, Dr. Khan has over 120 publications and presentations, including several white papers and a book entitled, Ligand-Binding Assays: Development, Validation, and Implementation in the Drug Development Arena—a consolidated and comprehensive reference widely used in the pharmaceutical industry.  Prior to joining Alliance Pharma, Dr. Khan had served in executive capacities at several major contract research organizations and pharmaceutical companies, including Phoenix International Life Sciences, NeuroBiotech, Medlmmune, Covance, and KCAS.  He earned his PhD degree in Biological Sciences from Aligarh University in India, followed by post-doctoral fellowships both at the National Institute of Environmental Health Sciences (NIEH) in North Carolina and at McGill University in Montreal.  Dr. Khan is a founding member of the Ligand-Binding Assay Bioanalytical Focus Group (LBABFG) at the American Association of Pharmaceutical Scientists (AAPS).  He has long been a contributing member at the AAPS, chairing and leading discussions on large molecule bioanalysis.  In recent years, he has served on several AAPS subcommittees geared toward formulating recommendations related to singleplex and multiplex biomarker assay validation, biomarker sample stability considerations, and creation of pharmaceutical grade kits for biomarker quantification.  He is recipient of 2016 AAPS Biotechnology section Distinguished Service Award.         Masood Khan, PhD, Vice President of Biopharmaceutical Services, is an internationally renowned thought leader in the field of regulatory compliant ligand-binding assays (LBAs).  Dr. Khan brings over 25 years of unparalleled knowledge of immunoanalytical sciences and technologies to head scientific operations and compliance of large molecule bioanalyses at Alliance Pharma.  To his credit, Dr. Khan has over 120 publications and presentations, including several white papers and a book entitled, Ligand-Binding Assays: Development, Validation, and Implementation in the Drug Development Arena—a consolidated and comprehensive reference widely used in the pharmaceutical industry.  Prior to joining Alliance Pharma, Dr. Khan had served in executive capacities at several major contract research organizations and pharmaceutical companies, including Phoenix International Life Sciences, NeuroBiotech, Medlmmune, Covance, and KCAS.  He earned his PhD degree in Biological Sciences from Aligarh University in India, followed by post-doctoral fellowships both at the National Institute of Environmental Health Sciences (NIEH) in North Carolina and at McGill University in Montreal.  Dr. Khan is a founding member of the Ligand-Binding Assay Bioanalytical Focus Group (LBABFG) at the American Association of Pharmaceutical Scientists (AAPS).  He has long been a contributing member at the AAPS, chairing and leading discussions on large molecule bioanalysis.  In recent years, he has served on several AAPS subcommittees geared toward formulating recommendations related to singleplex and multiplex biomarker assay validation, biomarker sample stability considerations, and creation of pharmaceutical grade kits for biomarker quantification.  He is recipient of 2016 AAPS Biotechnology section Distinguished Service Award.        

Research Interest

Host defense mechanisms,LPS effects on neurotransmitters